Taejoon Pharm, a leading specialty pharmaceutical company in Korea in ophthalmology sector, starting to make inroads into the U.S market.

Taejoon Pharm, a leading specialty pharma company in Korea in ophthalmology sector, made full-fledged entry into the U.S market

The company (co-chief executive officer Tae Young Lee and Joon Youb Lee), the only Korean company that exports aseptic opthalmic solutions to Europe told that it released its single use preservative-free eye drop called 'INFRESH PLUS EYE DROPS (Sodium Carboxymethyl Cellulose)' to the American market. Currently, large distribution companies in North America have sold the products and Taejoon Pharm would accelerate the global market exploration by extending the range of exports. INFRESH PLUS EYE DROP was selected as the 'COLUMBUS Project', which supports the advancement of the Korean healthcare industry to the North American market and entered to the North American market for a short time. Last year, it paved the road for the free exports to the European Free Trade Association and the EU associated countries without special certification procedure by achieving the CE, the integrated European certification mark, forming the foundation for a local Korean pharmaceutical company to directly export ophthalmic agents the European and American markets. Co-chief executive officer Joon Youb Lee, leading the exports and R&D of Taejoon Pharm, expressed his expectation, saying, "It is my pleasure to boast the techincal capability and quality of the company to the global market. During the last several years, Taejoon Pharm has invested the manpower, R&D and production in advanace. I will do my best to make the efforts realized".